Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial

Cardiovascular Diabetology
Atsushi TanakaPROCEED trial investigators

Abstract

Type 2 diabetes (T2D) is associated with renal impairment and vascular endothelial dysfunction. Therefore, this pathological connection is an important therapeutic target. Recent cardiovascular and renal outcome trials demonstrated that sodium glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risks of cardiovascular and renal events and mortality in patients with T2D and various other background risks including chronic kidney disease (CKD). However, the precise mechanisms by which SGLT2is accords these therapeutic benefits remain uncertain. It is also unknown whether these SGLT2is-associated benefits are associated with the amelioration of endothelial dysfunction in patients with T2D and CKD. The PROCEED trial is an investigator-initiated, prospective, multicenter, open-label, randomized-controlled trial. The target sample size is 110 subjects. After they furnish informed consent and their endothelial dysfunction is confirmed from their decreased reactive hyperemia indices (RHI), eligible participants with T2D (HbA1c, 6.0-9.0%) and established CKD (30 mL/min/1.73 m2 ≤ estimated glomerular filtration ratio [eGFR] < 60 and/or ≥ urine albumin-to-creatinine ratio 30 mg/g Cr) will be randomized (1:1) to receive e...Continue Reading

References

Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jul 10, 2003·American Heart Journal·Jeffrey T KuvinJames E Udelson
Oct 3, 2003·Journal of the American College of Cardiology·Michael E WidlanskyJoseph A Vita
Apr 29, 2004·JAMA : the Journal of the American Medical Association·James B MeigsJoAnn E Manson
Dec 8, 2004·Journal of the American College of Cardiology·Piero O BonettiAmir Lerman
Jan 26, 2005·Circulation·Amir Lerman, Andreas M Zeiher
Dec 3, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Barbara ThorandUNKNOWN MONICA/KORA Study Group
Dec 27, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mahmut Ilker YilmazCarmine Zoccali
May 4, 2013·European Heart Journal·Francesco PaneniFrancesco Cosentino
Mar 29, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Luca De NicolaRoberto Minutolo
Dec 4, 2014·Current Opinion in Nephrology and Hypertension·Marko Škrtić, David Z I Cherney
Feb 11, 2015·The Lancet. Diabetes & Endocrinology·Bin WangYan-Gang Wang
Mar 6, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Yasushi MatsuzawaAmir Lerman
Nov 11, 2015·Nature Reviews. Nephrology·Merlin C ThomasPaul Zimmet
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Aug 20, 2016·Journal of the American Society of Nephrology : JASN·Hiddo J L HeerspinkVlado Perkovic
Jan 4, 2017·Journal of cardiology·Atsushi Tanaka, Koichi Node
Feb 2, 2017·Journal of the American Society of Nephrology : JASN·Lennart TonneijckJaap A Joles
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
May 8, 2018·Kidney International·Hiddo J L HeerspinkDavid Z I Cherney
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Sep 5, 2018·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Christopher JepsonUNKNOWN Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
Oct 26, 2018·Hypertension·Atsushi TanakaUNKNOWN Physiological Diagnosis Criteria for Vascular Failure Committee
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Jun 5, 2019·The Journal of Clinical Endocrinology and Metabolism·Anna SoliniRosa Maria Bruno
Jun 7, 2019·Cardiovascular Diabetology·Akira SezaiMasashi Tanaka

❮ Previous
Next ❯

Citations

Aug 12, 2021·Heart Failure Reviews·Michele CorrealeNatale Daniele Brunetti
Sep 15, 2021·Cardiovascular Drugs and Therapy·Michele CorrealeNatale Daniele Brunetti

❮ Previous
Next ❯

Software Mentioned

PAT
PAT2000
Endo
RH

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.